• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢癌中异常的胆固醇代谢:新型治疗靶点的鉴定

Aberrant Cholesterol Metabolism in Ovarian Cancer: Identification of Novel Therapeutic Targets.

作者信息

He Jiangnan, Siu Michelle K Y, Ngan Hextan Y S, Chan Karen K L

机构信息

Departments of Obstetrics and Gynaecology, Li Ka Shing (LKS) Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong, SAR China.

出版信息

Front Oncol. 2021 Nov 8;11:738177. doi: 10.3389/fonc.2021.738177. eCollection 2021.

DOI:10.3389/fonc.2021.738177
PMID:34820325
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8606538/
Abstract

Cholesterol is an essential substance in mammalian cells, and cholesterol metabolism plays crucial roles in multiple biological functions. Dysregulated cholesterol metabolism is a metabolic hallmark in several cancers, beyond the Warburg effect. Reprogrammed cholesterol metabolism has been reported to enhance tumorigenesis, metastasis and chemoresistance in multiple cancer types, including ovarian cancer. Ovarian cancer is one of the most aggressive malignancies worldwide. Alterations in metabolic pathways are characteristic features of ovarian cancer; however, the specific role of cholesterol metabolism remains to be established. In this report, we provide an overview of the key proteins involved in cholesterol metabolism in ovarian cancer, including the rate-limiting enzymes in cholesterol biosynthesis, and the proteins involved in cholesterol uptake, storage and trafficking. Also, we review the roles of cholesterol and its derivatives in ovarian cancer and the tumor microenvironment, and discuss promising related therapeutic targets for ovarian cancer.

摘要

胆固醇是哺乳动物细胞中的一种必需物质,胆固醇代谢在多种生物学功能中发挥着关键作用。除了瓦伯格效应外,胆固醇代谢失调是几种癌症的代谢特征。据报道,重编程的胆固醇代谢会增强多种癌症类型(包括卵巢癌)的肿瘤发生、转移和化疗耐药性。卵巢癌是全球最具侵袭性的恶性肿瘤之一。代谢途径的改变是卵巢癌的特征性表现;然而,胆固醇代谢的具体作用仍有待确定。在本报告中,我们概述了卵巢癌中参与胆固醇代谢的关键蛋白,包括胆固醇生物合成中的限速酶,以及参与胆固醇摄取、储存和运输的蛋白。此外,我们还综述了胆固醇及其衍生物在卵巢癌和肿瘤微环境中的作用,并讨论了卵巢癌有前景的相关治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1a9/8606538/a8b64fa3b965/fonc-11-738177-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1a9/8606538/a8b64fa3b965/fonc-11-738177-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1a9/8606538/a8b64fa3b965/fonc-11-738177-g001.jpg

相似文献

1
Aberrant Cholesterol Metabolism in Ovarian Cancer: Identification of Novel Therapeutic Targets.卵巢癌中异常的胆固醇代谢:新型治疗靶点的鉴定
Front Oncol. 2021 Nov 8;11:738177. doi: 10.3389/fonc.2021.738177. eCollection 2021.
2
The "Sweet Spot" of Targeting Tumor Metabolism in Ovarian Cancers.卵巢癌中靶向肿瘤代谢的“甜蜜点”
Cancers (Basel). 2022 Sep 27;14(19):4696. doi: 10.3390/cancers14194696.
3
Metabolic orchestration between cancer cells and tumor microenvironment as a co-evolutionary source of chemoresistance in ovarian cancer: a therapeutic implication.癌细胞与肿瘤微环境之间的代谢协同作用是卵巢癌化疗耐药性的共同进化来源:治疗意义。
Biochem Pharmacol. 2014 Nov 1;92(1):43-54. doi: 10.1016/j.bcp.2014.08.011. Epub 2014 Aug 25.
4
Lipid metabolism in tumor microenvironment: novel therapeutic targets.肿瘤微环境中的脂质代谢:新型治疗靶点
Cancer Cell Int. 2022 Jul 5;22(1):224. doi: 10.1186/s12935-022-02645-4.
5
Deregulation of Lipid Metabolism: The Critical Factors in Ovarian Cancer.脂质代谢失调:卵巢癌的关键因素
Front Oncol. 2020 Oct 19;10:593017. doi: 10.3389/fonc.2020.593017. eCollection 2020.
6
Targeting cholesterol metabolism in Cancer: From molecular mechanisms to therapeutic implications.靶向癌症中的胆固醇代谢:从分子机制到治疗意义。
Biochem Pharmacol. 2023 Dec;218:115907. doi: 10.1016/j.bcp.2023.115907. Epub 2023 Nov 4.
7
Warburg and Beyond: The Power of Mitochondrial Metabolism to Collaborate or Replace Fermentative Glycolysis in Cancer.瓦伯格效应及其他:线粒体代谢在癌症中协同或替代发酵性糖酵解的作用
Cancers (Basel). 2020 Apr 30;12(5):1119. doi: 10.3390/cancers12051119.
8
CD44 in Ovarian Cancer Progression and Therapy Resistance-A Critical Role for STAT3.CD44在卵巢癌进展和治疗耐药中的作用——STAT3的关键作用
Front Oncol. 2020 Dec 1;10:589601. doi: 10.3389/fonc.2020.589601. eCollection 2020.
9
Cholesterol Homeostasis Modulates Platinum Sensitivity in Human Ovarian Cancer.胆固醇代谢稳态调控人卵巢癌细胞铂类药物敏感性
Cells. 2020 Mar 30;9(4):828. doi: 10.3390/cells9040828.
10
NKX2-8 deletion-induced reprogramming of fatty acid metabolism confers chemoresistance in epithelial ovarian cancer.NKX2-8 缺失诱导的脂肪酸代谢重编程赋予上皮性卵巢癌化疗耐药性。
EBioMedicine. 2019 May;43:238-252. doi: 10.1016/j.ebiom.2019.04.041. Epub 2019 Apr 29.

引用本文的文献

1
Hypoxia alters the response of ovarian cancer cells to the mitomycin C drug.缺氧会改变卵巢癌细胞对丝裂霉素C药物的反应。
Front Cell Dev Biol. 2025 Jun 13;13:1575134. doi: 10.3389/fcell.2025.1575134. eCollection 2025.
2
Targeting ferroptosis: a promising avenue for ovarian cancer treatment.靶向铁死亡:卵巢癌治疗的一条有前景的途径。
Front Immunol. 2025 Jun 5;16:1578723. doi: 10.3389/fimmu.2025.1578723. eCollection 2025.
3
Mechanical cues rewire lipid metabolism and support chemoresistance in epithelial ovarian cancer cell lines OVCAR3 and SKOV3.

本文引用的文献

1
Cholesterol-Induced Metabolic Reprogramming in Breast Cancer Cells Is Mediated via the ERRα Pathway.胆固醇诱导的乳腺癌细胞代谢重编程通过ERRα途径介导。
Cancers (Basel). 2021 May 26;13(11):2605. doi: 10.3390/cancers13112605.
2
MIEF2 reprograms lipid metabolism to drive progression of ovarian cancer through ROS/AKT/mTOR signaling pathway.MIEF2 通过 ROS/AKT/mTOR 信号通路重编程脂质代谢以推动卵巢癌的进展。
Cell Death Dis. 2021 Jan 5;12(1):18. doi: 10.1038/s41419-020-03336-6.
3
Liver X Receptors: Regulators of Cholesterol Metabolism, Inflammation, Autoimmunity, and Cancer.
机械信号重塑上皮性卵巢癌细胞系OVCAR3和SKOV3中的脂质代谢并支持化疗耐药性。
Cell Commun Signal. 2025 Apr 22;23(1):193. doi: 10.1186/s12964-025-02144-9.
4
Navigating Metabolic Challenges in Ovarian Cancer: Insights and Innovations in Drug Repurposing.应对卵巢癌中的代谢挑战:药物重新利用的见解与创新
Cancer Med. 2025 Feb;14(4):e70681. doi: 10.1002/cam4.70681.
5
Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials.尼拉帕利与他汀类药物在卵巢癌临床试验中的潜在协同效应。
Cancer Res Commun. 2025 Jan 1;5(1):178-186. doi: 10.1158/2767-9764.CRC-24-0191.
6
Targeting Mitochondrial Cholesterol Efflux via TCF21/ABCA10 Pathway to Enhance Cisplatin Efficacy in Ovarian Cancer.通过TCF21/ABCA10途径靶向线粒体胆固醇流出以增强顺铂在卵巢癌中的疗效
Biochem Genet. 2024 Oct 22. doi: 10.1007/s10528-024-10939-7.
7
Why make it if you can take it: review on extracellular cholesterol uptake and its importance in breast and ovarian cancers.如果可以摄取,为什么要制造它:细胞外胆固醇摄取及其在乳腺癌和卵巢癌中的重要性综述。
J Exp Clin Cancer Res. 2024 Sep 6;43(1):254. doi: 10.1186/s13046-024-03172-y.
8
Ovarian cancer ascites proteomic profile reflects metabolic changes during disease progression.卵巢癌腹水蛋白质组学图谱反映疾病进展过程中的代谢变化。
Biochem Biophys Rep. 2024 Jun 13;39:101755. doi: 10.1016/j.bbrep.2024.101755. eCollection 2024 Sep.
9
Pre-operative levels of angiopoietin protein-like 3 (ANGPTL3) in women diagnosed with high-grade serous carcinoma of the ovary.术前女性高级别浆液性卵巢癌中血管生成素样蛋白 3(ANGPTL3)的水平。
Lipids Health Dis. 2024 Feb 27;23(1):59. doi: 10.1186/s12944-024-02038-8.
10
Enhancing Immunotherapy in Ovarian Cancer: The Emerging Role of Metformin and Statins.增强卵巢癌的免疫疗法:二甲双胍和他汀类药物的新作用。
Int J Mol Sci. 2023 Dec 25;25(1):323. doi: 10.3390/ijms25010323.
肝 X 受体:胆固醇代谢、炎症、自身免疫和癌症的调节剂。
Front Immunol. 2020 Nov 3;11:584303. doi: 10.3389/fimmu.2020.584303. eCollection 2020.
4
PGC1α regulates mitochondrial oxidative phosphorylation involved in cisplatin resistance in ovarian cancer cells via nucleo-mitochondrial transcriptional feedback.PGC1α 通过核-线粒体转录反馈调节卵巢癌细胞中涉及顺铂耐药的线粒体氧化磷酸化。
Exp Cell Res. 2021 Jan 1;398(1):112369. doi: 10.1016/j.yexcr.2020.112369. Epub 2020 Nov 18.
5
Deregulation of Lipid Metabolism: The Critical Factors in Ovarian Cancer.脂质代谢失调:卵巢癌的关键因素
Front Oncol. 2020 Oct 19;10:593017. doi: 10.3389/fonc.2020.593017. eCollection 2020.
6
Roles of Farnesyl-Diphosphate Farnesyltransferase 1 in Tumour and Tumour Microenvironments.法尼基二磷酸法尼基转移酶 1 在肿瘤和肿瘤微环境中的作用。
Cells. 2020 Oct 25;9(11):2352. doi: 10.3390/cells9112352.
7
20(S)-Rg3 upregulates FDFT1 via reducing miR-4425 to inhibit ovarian cancer progression.20(S)-Rg3 通过降低 miR-4425 水平来上调 FDFT1,从而抑制卵巢癌细胞的进展。
Arch Biochem Biophys. 2020 Oct 30;693:108569. doi: 10.1016/j.abb.2020.108569. Epub 2020 Sep 1.
8
Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer.抑制甲羟戊酸途径对卵巢癌的抗肿瘤作用。
BMC Cancer. 2020 Jul 29;20(1):703. doi: 10.1186/s12885-020-07164-x.
9
Cholesterol metabolism: New functions and therapeutic approaches in cancer.胆固醇代谢:癌症的新功能和治疗方法。
Biochim Biophys Acta Rev Cancer. 2020 Aug;1874(1):188394. doi: 10.1016/j.bbcan.2020.188394. Epub 2020 Jul 19.
10
SOAT1 promotes mevalonate pathway dependency in pancreatic cancer.SOAT1 促进胰腺癌中甲羟戊酸途径的依赖性。
J Exp Med. 2020 Sep 7;217(9). doi: 10.1084/jem.20192389.